PSMA PET/CT clearly differentiates prostate cancer from benign tissue

(Society of Nuclear Medicine and Molecular Imaging) Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in the February issue of The Journal of Nuclear Medicine and demonstrates that the maximum standardized uptake value (SUVmax) on 68Ga-PSMA PET/CT scans correlates with PSMA-expression in primary prostate cancer. By this means, researchers were able to generate an SUVmax cutoff for the differentiation of cancerous and benign prostate tissue.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Topline results seem to give support to Blue Earth Diagnostics’ test to help impact treatment decisions for patients. The Burlington, MA-based company presented results from the LOCATE investigational trial at the American Urology Association’s annual meeting. LOCATE is a prospective, multi-center, open label study conducted at 15 sites in the U.S. The study’s primary endpoint measured the percentage of men with suspected biochemical recurrence of prostate cancer following initial prior therapy whose treatment plan was changed following Blue Earth Diagnostics’ 18F fluciclovine PET/CT scan. The ...
Source: MDDI - Category: Medical Devices Authors: Tags: Imaging Source Type: news
By SAURABH JHA Of my time arguing with doctors, 30 % is spent convincing British doctors that their American counterparts aren’t idiots, 30 % convincing American doctors that British doctors aren’t idiots, and 40 % convincing both that I’m not an idiot. A British doctor once earnestly asked whether American physicians carry credit card reading machines inside their white coats. Myths about the NHS can be equally comical. British doctors don’t prostate every morning in deference to the NHS, like the citizens of Oceania sang to Big Brother in Orwell’s dystopia. Nor, in their daily rounds, do the...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: OP-ED Uncategorized AlfieEvans Source Type: blogs
Conclusions64Cu NODAGA-PSMA PET is a promising imaging tool in the detection of residual disease in patients with recurrent or primary progressive prostate cancer. Furthermore, the increased tracer uptake over time indicates in vivo stability of the diagnostic radiopharmaceutical.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
AbstractPurposeIn this prospective study, we evaluated the optimal time-point for68Ga-PSMA-11 PET/CT acquisition in the assessment of prostate cancer. We also examined, for the first time the feasibility of tracer production using a PSMA-11 sterile cold-kit in the clinical workflow of PET/CT centres.MethodsFifty prostate cancer patients (25 staging, 25 biochemical recurrence) were enrolled in this study. All patients received an intravenous dose of 2.0  MBq/kg body weight68Ga-PSMA-11 prepared using a sterile cold kit (ANMI SA, Liege, Belgium), followed by an early (20  min after injection) semi-whole-body PET/CT ...
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Authors: Soydal C, Urun Y, Suer E, Nak D, Ozkan E, Kucuk ON Abstract BACKGROUND: The aim of this study is to evaluate predictive factors of 68Gallium (68Ga) Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET)/Computed Tomography (CT) positivity. METHODS: Relationships between serum Prostate Specific Antigen (PSA), Lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) levels, Gleason Score (GS) and positivity of 68Ga PSMA PET in patients who underwent 68Ga PSMA PET/CT for restaging for PCa were evaluated retrospectively. RESULTS: One hundred and four (median age: 67; range: 51-8...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research
We present the case of a 30-year-old woman with triple-negative bilateral breast carcinoma who underwent bilateral mastectomy, chemotherapy, and radiotherapy. She developed a left chest wall and liver recurrence after primary therapy. Her recurrent disease was also triple-negative. In view of the known poor prognosis and very limited therapeutic options, we performed 68Ga-PSMA PET/CT scan to explore the possibility of PSMA-based therapy as a future option after exhausting standard-of-care treatments.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
AbstractPurposeThe aims of this retrospective analysis were to compare68Ga-PSMA PET findings and low-dose CT findings (120  kV, 30 mA), and to obtain semiquantitative and quantitative68Ga-PSMA PET data in patients with prostate cancer (PC) bone metastases.MethodsIn total, 152 PET/CT scans from 140 patients were evaluated. Of these patients, 30 had previously untreated primary PC, and 110 had biochemical relapse after treatment of primary PC. All patients underwent dynamic PET/CT scanning of the pelvis and lower abdomen as well as whole-body PET/CT with68Ga-PSMA-11. The PET/CT scans were analysed qualitatively (vi...
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Conclusions99mTc-maraciclatide accumulates in PCa bone metastases in keeping with increased αvβ3 integrin expression. Greater activity in metastases with lower CT density suggests that uptake is related to osteoclast activity. Changes in planar and SPECT T:M ratios after 12  weeks of treatment differed between patients with and without PD and99mTc-maraciclatide imaging may be a potential method for assessing early response.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
AbstractPurposePrevious studies in prostate cancer (PCa) patients tried to correlate the onset of local recurrence (LR) with the development of distant metastases and formulated, based on theoretical and experimental data, hypotheses linking the two events. We aimed to address this issue with11C-choline positron emission tomography/computed tomography (PET/CT).MethodsThis retrospective study included 491 PCa patients previously treated with radical prostatectomy who had undergone11C-choline PET/CT owing to biochemical failure. Further inclusion criteria were availability of clinical and pathological variables for survival ...
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Conclusions18F-DCFPyL dosimetry in nine patients was obtained using novel models for the lacrimal and salivary glands, two organs with potentially dose-limiting uptake for therapy and diagnosis which lacked pre-existing models.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
More News: Cancer | Cancer & Oncology | CT Scan | Germany Health | Nuclear Medicine | PET Scan | Prostate Cancer